Sentence examples for better in the majority from inspiring English sources

It is expected that by using not averaged values, or averaged over shorter periods, results would be better in the majority of cases.

Patients reported feeling better in the majority of cases (56%), and feeling the same in almost a third of cases (31%).

Likelihood ratio tests comparing these two models with 51 (= 60 - 9) degrees of freedom suggested statistically significant differences for 2,625 of 3,622 (72.5%) orthologous genes, and the second model was better in the majority of cases.

Again, the SemiSVR performed better in the majority of cases (18 of 23 PDZ domains; Table 3)—see Section 3.2 for an investigation into the domains that were poorly predicted.

The results from our simulation study show that the outcome of vaccination would be better in the majority of scenarios/subgroups (RR<1 in 63.9% of scenarios considered) but worse in a substantial proportion of scenarios considered (RR ≥1 in 36.1% of the scenarios).

Even though urban participants showed better scores in the majority of EUROFIT tests, physical fitness of the total population was lower compared to that of adolescents from other countries.

However, the authors suggest that insufficient centralisation of the femoral head may induce subluxation in early childhood, which commonly requires additional corrective surgery for acquiring better congruency in the majority of these hip joints, as shown in this study; thus according to the authors, the purpose of second stage osteotomy is to acquire better congruency of the hip joint.

All of these banks offer other accounts with better benefits, though in the majority of cases you now have to pay a fee for these.

Applied to the Taylor method, it has presented a lower or similar cost compared to the state-of-the-art Padé algorithms with better accuracy results in the majority of test matrices, avoiding Padé's denominator condition problems.

In general, patients receiving deferasirox 5 mg/kg/day and 10 mg/kg/day starting doses had better LIC responses in the majority of subgroups compared with placebo as shown by the point estimates of the differences favoring the deferasirox 10 mg/kg/day and 5 mg/kg/day starting dose arms (Fig. 1A,B).

More recently, the combination of conventional chemotherapy with molecular targeted therapies such as anti-vascular endothelial growth factor (anti-VEGF) agents bevacizumab (Avastin®) and aflibercept (Zaltrap®) or anti-epidermal growth factor receptor (anti-EGFR) agents cetuximab (Erbitux®) and panitumumab (Vectibix®) showed better treatment outcomes in the majority of mCRC patients.